Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 09:32:59 UTC
Update Date2021-09-26 23:04:11 UTC
HMDB IDHMDB0251903
Secondary Accession NumbersNone
Metabolite Identification
Common NameErdafitinib
DescriptionErdafitinib belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group. Erdafitinib is a very strong basic compound (based on its pKa). Researchers have investigated erdafitinib for safety and efficacy in treatment of cholangiocarcinoma, gastric cancer, non-small cell lung cancer, and esophageal cancer. Erdafitinib is a small molecule inhibitor of FGFR approved for treatment of cancer and marketed under the name Balversa. In April 2019, erdafitinib was granted approval by the FDA for treatment of metastatic or locally advanced bladder cancer with an FGFR3 or FGFR2 alteration that has progressed beyond traditional platinum-based therapies, subject to a confirmatory trial. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. In March 2018, erdafitinib was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for treatment of urothelial cancer. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development. This compound has been identified in human blood as reported by (PMID: 31557052 ). Erdafitinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Erdafitinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
Synonyms
ValueSource
JNJ-42756493ERDAFITINIBChEMBL
Chemical FormulaC25H30N6O2
Average Molecular Weight446.555
Monoisotopic Molecular Weight446.24302423
IUPAC NameN-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-N-{2-[(propan-2-yl)amino]ethyl}quinoxalin-6-amine
Traditional NameN-(3,5-dimethoxyphenyl)-N-[2-(isopropylamino)ethyl]-3-(1-methylpyrazol-4-yl)quinoxalin-6-amine
CAS Registry NumberNot Available
SMILES
COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1
InChI Identifier
InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3
InChI KeyOLAHOMJCDNXHFI-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
KingdomOrganic compounds
Super ClassOrganic nitrogen compounds
ClassOrganonitrogen compounds
Sub ClassAmines
Direct ParentAlkyldiarylamines
Alternative Parents
Substituents
  • Alkyldiarylamine
  • Diazanaphthalene
  • Quinoxaline
  • Dimethoxybenzene
  • M-dimethoxybenzene
  • Aminophenyl ether
  • Methoxyaniline
  • Phenoxy compound
  • Phenol ether
  • Aniline or substituted anilines
  • Anisole
  • Methoxybenzene
  • Alkyl aryl ether
  • Pyrazine
  • Benzenoid
  • Monocyclic benzene moiety
  • Azole
  • Heteroaromatic compound
  • Pyrazole
  • Azacycle
  • Secondary aliphatic amine
  • Ether
  • Organoheterocyclic compound
  • Secondary amine
  • Organopnictogen compound
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP3.57ALOGPS
logP3.52ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)9.72ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.33 ŲChemAxon
Rotatable Bond Count9ChemAxon
Refractivity139.32 m³·mol⁻¹ChemAxon
Polarizability51 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+208.00230932474
DeepCCS[M-H]-205.64430932474
DeepCCS[M-2H]-238.64930932474
DeepCCS[M+Na]+214.18430932474
AllCCS[M+H]+212.132859911
AllCCS[M+H-H2O]+210.032859911
AllCCS[M+NH4]+214.132859911
AllCCS[M+Na]+214.732859911
AllCCS[M-H]-208.032859911
AllCCS[M+Na-2H]-208.532859911
AllCCS[M+HCOO]-209.232859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
ErdafitinibCOC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C15104.7Standard polar33892256
ErdafitinibCOC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C13743.3Standard non polar33892256
ErdafitinibCOC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C14315.2Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Erdafitinib,1TMS,isomer #1COC1=CC(OC)=CC(N(CCN(C(C)C)[Si](C)(C)C)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)=C14051.1Semi standard non polar33892256
Erdafitinib,1TMS,isomer #1COC1=CC(OC)=CC(N(CCN(C(C)C)[Si](C)(C)C)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)=C14183.8Standard non polar33892256
Erdafitinib,1TMS,isomer #1COC1=CC(OC)=CC(N(CCN(C(C)C)[Si](C)(C)C)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)=C15215.1Standard polar33892256
Erdafitinib,1TBDMS,isomer #1COC1=CC(OC)=CC(N(CCN(C(C)C)[Si](C)(C)C(C)(C)C)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)=C14241.9Semi standard non polar33892256
Erdafitinib,1TBDMS,isomer #1COC1=CC(OC)=CC(N(CCN(C(C)C)[Si](C)(C)C(C)(C)C)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)=C14342.4Standard non polar33892256
Erdafitinib,1TBDMS,isomer #1COC1=CC(OC)=CC(N(CCN(C(C)C)[Si](C)(C)C(C)(C)C)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)=C15206.3Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Erdafitinib GC-MS (Non-derivatized) - 70eV, Positivesplash10-008l-9037500000-824da90d87cce468e73e2021-09-24Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Erdafitinib GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 10V, Positive-QTOFsplash10-0002-1002900000-329c87c0b7108105980e2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 20V, Positive-QTOFsplash10-000i-6009300000-1189aff9b625e05f6c192017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 40V, Positive-QTOFsplash10-001u-5009000000-d0830ff9563fdd383c882017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 10V, Negative-QTOFsplash10-0002-1000900000-acbafbb13aea25b4a9c22017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 20V, Negative-QTOFsplash10-0uxs-2002900000-4c10015c422a5a1c197a2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 40V, Negative-QTOFsplash10-053r-9006200000-a158b08c0077f58b832d2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 10V, Positive-QTOFsplash10-000b-0007900000-b7030e7e69f37d0957242021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 20V, Positive-QTOFsplash10-000i-1009200000-ea7c528ebbcb8493b7b62021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 40V, Positive-QTOFsplash10-0006-9035100000-93ee86f9ecab4b5660f32021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 10V, Negative-QTOFsplash10-0002-0002900000-7895805c86d6cefb6c5d2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 20V, Negative-QTOFsplash10-03di-0009000000-b7870d8b8942d080b11b2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Erdafitinib 40V, Negative-QTOFsplash10-008c-0049100000-631ab9527480ff69a4972021-10-12Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB12147
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkErdafitinib
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]